In:
Therapeutic Apheresis and Dialysis, Wiley, Vol. 18, No. S2 ( 2014-06), p. 19-23
Abstract:
Bixalomer (Bix) is an amine‐functional polymer, non‐calcium‐containing phosphate ( P ) binder, and has been clinically available in J apan recently. Bix is expected to cause fewer gastrointestinal ( GI ) side‐effects as compared with sevelamer hydrochloride ( SH ), because of less expansion of Bix in the GI tract. In this prospective observational study, we evaluated changes in GI symptoms by the Gastrointestinal Symptom Rating Scale ( GSRS ) score in long‐term hemodialysis ( HD ) outpatients with SH ‐associated GI symptoms who switched to Bix from SH . A total of 114 patients (age 63.7 ± 10.8 year (mean ± SD ), female 65.5%, HD vintage 11.2 ± 8.6 years, diabetes mellitus 27.4%) were enrolled. The GSRS score was checked at 0 and 12 weeks after the start of Bix. Bix was started at the initial dose of 750 mg/day, and then was titrated. Serum albumin, P and corrected calcium levels did not significantly change during Bix treatment. However, serum low‐density lipoprotein‐cholesterol and bicarbonate levels significantly increased during Bix treatment ( P 〈 0.001). In GSRS scores, total and domain‐specific scores, including constipation, diarrhea, reflux and abdominal pain were significantly reduced at 0, 4, 12 and 24 weeks as compared with those at 0 weeks ( P 〈 0.05). This study shows that Bix was well tolerated and managed hyperphosphatemia effectively after switching from SH in Japanese patients on long‐term HD . In addition, Bix might be less often associated with GI symptoms as compared with SH .
Type of Medium:
Online Resource
ISSN:
1744-9979
,
1744-9987
DOI:
10.1111/tap.2014.18.issue-s2
DOI:
10.1111/1744-9987.12229
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2010864-3
Bookmarklink
